The EU's IP strategy: Enabler or barrier?EPHA #A2MDialogues
27 October 2020
Our second dialogue in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.
Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.
How do we ensure that IP incentives compensate and reward innovation but do not distort competition?
What lessons have we learned on IP in the response to COVID19?
Patent-driven innovation may work for profit-driven drug development but it reflects a R&I agenda which favours profit prospects, distortion of competition and market dominance. Additionally, it leads to excessive, unaffordable prices due to monopoly and can stifle meaningful innovation
As the EU prepares to present its IP strategy as well as the scenarios for a review of the legislation on orphan and paediatric medicines, join our experts and key stakeholders who will discuss what change is necessary to serve the needs of all patients while guaranteeing healthy prices and competition
Policy Officer, DG Internal Market, Industry, Entrepreneurship and SMEs (DG Growth)
EU Policy & Advocacy Advisor
Médecins Sans Frontières Access Campaign
General Counsel & External Relations Director
Medicines for Europe
Thyra de Jongh
Policy Manager, Universal Access to Affordable Medicines
European Public Health Alliance
On Social Media
Dimitri makes two very stong points. Patent quality and lack of transparency re R&D cost of drug development. EPO do not always have the mechanism to test if the claims made in application are robust. Perhaps bring leg to force pharma sector to open up re R&D cost #A2MDialogues— Kanaddy (@DKanaddy) October 27, 2020
Why this hesitation to use the words "compulsory licensing" especially during pandemic times in relation to #A2M access to medicines? Sergio Napolitano finally mentions the Competition Commission. CC need to use exclusionary abuse rules to deal wth excessive pricing #A2MDialogues— Kanaddy (@DKanaddy) October 27, 2020